Navigation Links
Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Date:10/4/2011

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ -- Kylin Therapeutics, Inc., a leading second-generation RNAi company, announced today that it has received a notice of allowance from United States Patent and Trademark Office (USPTO) for its second U.S. patent application. This newly allowed patent broadly covers new therapeutic RNA technology, as well as expanded areas on Kylin's proprietary nanoparticle technology platform, "pRNA" ("packaging RNA"). This new intellectual property covers multi-valent RNA structures broadly encompassing: tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA interference. "We continue to be gratified that the USPTO recognizes pRNA as an entirely unique platform in the crowded RNAi intellectual property space," said J. Eric Davis, J.D., President and Chief Executive Officer of Kylin Therapeutics, Inc.

Upon issuance, this will be Kylin's second U.S. patent. Along with its other issued and granted pRNA patents in Europe, Australia, and the United States, Kylin believes that this seminal patent family represents rare "new ground" in the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five patent families, with several other applications in the pipeline. "The unexpected, pharmacologically robust nature of the pRNA platform continues to allow Kylin to claim more ground in areas such as RNAi and tissue-specific targeting," said Homer Pearce, Ph.D., Director and Chairman of Kylin's Scientific Advisory Board.

Kylin's pRNA intellectual property estate is based upon the innovative discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and creation of novel, therapeutically relevant RNA molecules. These molecules can be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates and tissue-targeting modalities, and they can be used systemically and discretely without additional delivery components. Kylin has continued and expanded upon the work of Dr. Gu
'/>"/>

SOURCE Kylin Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Skyline Diagnostics Establishes Research Collaboration With Janssen
2. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
5. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
6. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
7. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
8. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Inc. (Nasdaq: IDEV ) announced today the ... entitled "Once Daily Dosage Forms,of Trospium," which is ... Supernus Pharmaceuticals, Inc., The ,978 patent covers ... of trospium chloride which is indicated for the,treatment ...
... BRUNSWICK, N.J., Aug. 13 At the upcoming ... R&D Team,Leader, will present "Silicone Elastomer Gels: New ... place in Philadelphia, September 16-17., According to ... molecular,structures that provide differentiated performance features for wound ...
... - Test Cleared to Screen Donated Blood for Hepatitis ... C, on Fully and Semi-Automated Instrument Systems -, ... ) announced today that the US Food and Drug ... the,PROCLEIX(R) ULTRIO(R) assay to screen donated blood for the ...
Cached Biology Technology:Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 3Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4
(Date:7/24/2014)... electric cars ply silent freeways, solar panels blanket rooftops ... earth, from howling winds and from the blazing desert ... is technically and economically feasible to convert California,s all-purpose ... Published in Energy , the plan shows the ... in California that could create tens of thousands of ...
(Date:7/24/2014)... has its own microbial terroir, meaning the microbial populations ... in the product, creating the final flavor according to ... Applied and Environmental Microbiology . This is the first ... sake brewery. , Many sake makers inoculate with ... Mills of the University of California, Davis, but he ...
(Date:7/24/2014)... low vision specialist at The University of Texas Health ... awarded a grant to help Harris County residents whose ... surgery. , Even with corrective lenses, many people with ... are a variety of low vision devices, such as ... vision loss. , Iyer is using the three-year, $164,645 ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4The microbes make the sake brewery 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
... Vascular and Interventional Radiology ,s impact factorthe measure of ... of article citations compared to the total number of ... journal,s quality and influence has remained consistently high over ... been enhanced recently by the increased use of new ...
... A University of Colorado School of Medicine scientist is ... could boost cognitive function in those with Down syndrome, ... potential milestone in research on this genetic condition. ... those with Down syndrome," said Alberto Costa, MD, PhD, ...
... with over half with a depth greater than 3000 ... know that the deep ocean contains a diversity of ... biological and mineral resources. Human activities are, however increasingly ... loss and, with this, the loss of many goods ...
Cached Biology News:Journal of Vascular and Interventional Radiology increases impact, offers new initiatives 2Journal of Vascular and Interventional Radiology increases impact, offers new initiatives 3Researcher tests promising drug on those with Down syndrome 2Man and the last great wilderness: Human impact on the deep sea 2Man and the last great wilderness: Human impact on the deep sea 3Man and the last great wilderness: Human impact on the deep sea 4
Lipid Phosphate Phosphohydrolase 2...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: